Isoprostanoids in Clinical and Experimental Neurological Disease Models
Isoprostanoids are a large family of compounds derived from non-enzymatic oxidation of polyunsaturated fatty acids (PUFAs). Unlike other oxidative stress biomarkers, they provide unique information on the precursor of the targeted PUFA. Although they were discovered about a quarter of century ago, t...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-07-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-3921/7/7/88 |
| _version_ | 1827842993385635840 |
|---|---|
| author | Cinzia Signorini Claudio De Felice Jean-Marie Galano Camille Oger Silvia Leoncini Alessio Cortelazzo Lucia Ciccoli Thierry Durand Joussef Hayek Jetty Chung-Yung Lee |
| author_facet | Cinzia Signorini Claudio De Felice Jean-Marie Galano Camille Oger Silvia Leoncini Alessio Cortelazzo Lucia Ciccoli Thierry Durand Joussef Hayek Jetty Chung-Yung Lee |
| author_sort | Cinzia Signorini |
| collection | DOAJ |
| description | Isoprostanoids are a large family of compounds derived from non-enzymatic oxidation of polyunsaturated fatty acids (PUFAs). Unlike other oxidative stress biomarkers, they provide unique information on the precursor of the targeted PUFA. Although they were discovered about a quarter of century ago, the knowledge on the role of key isoprostanoids in the pathogenesis of experimental and human disease models remains limited. This is mainly due to the limited availability of highly purified molecules to be used as a reference standard in the identification of biological samples. The accurate knowledge on their biological relevance is the critical step that could be translated from some mere technical/industrial advances into a reliable biological disease marker which is helpful in deciphering the oxidative stress puzzle related to neurological disorders. Recent research indicates the value of isoprostanoids in predicting the clinical presentation and evolution of the neurological diseases. This review focuses on the relevance of isoprostanoids as mediators and potential biomarkers in neurological diseases, a heterogeneous family ranging from rare brain diseases to major health conditions that could have worldwide socioeconomic impact in the health sector. The current challenge is to identify the preferential biochemical pathways that actually follow the oxidative reactions in the neurological diseases and the consequence of the specific isoprostanes in the underlying pathogenic mechanisms. |
| first_indexed | 2024-03-12T08:18:21Z |
| format | Article |
| id | doaj.art-f466414f146b46c493b33e16c6d5f5f9 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-12T08:18:21Z |
| publishDate | 2018-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-f466414f146b46c493b33e16c6d5f5f92023-09-02T18:44:32ZengMDPI AGAntioxidants2076-39212018-07-01778810.3390/antiox7070088antiox7070088Isoprostanoids in Clinical and Experimental Neurological Disease ModelsCinzia Signorini0Claudio De Felice1Jean-Marie Galano2Camille Oger3Silvia Leoncini4Alessio Cortelazzo5Lucia Ciccoli6Thierry Durand7Joussef Hayek8Jetty Chung-Yung Lee9Department of Molecular and Developmental Medicine, University of Siena, I-53100 Siena, ItalyNeonatal Intensive Care Unit, Azienda Ospedaliera Universitaria Senese, I-53100 Siena, ItalyInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34093 Montpellier CEDEX 05, FranceInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34093 Montpellier CEDEX 05, FranceChild Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, I-53100 Siena, ItalyChild Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, I-53100 Siena, ItalyDepartment of Molecular and Developmental Medicine, University of Siena, I-53100 Siena, ItalyInstitut des Biomolécules Max Mousseron (IBMM), UMR 5247, Université de Montpellier, CNRS, ENSCM, F-34093 Montpellier CEDEX 05, FranceChild Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, I-53100 Siena, ItalySchool of Biological Sciences, The University of Hong Kong, Hong Kong, ChinaIsoprostanoids are a large family of compounds derived from non-enzymatic oxidation of polyunsaturated fatty acids (PUFAs). Unlike other oxidative stress biomarkers, they provide unique information on the precursor of the targeted PUFA. Although they were discovered about a quarter of century ago, the knowledge on the role of key isoprostanoids in the pathogenesis of experimental and human disease models remains limited. This is mainly due to the limited availability of highly purified molecules to be used as a reference standard in the identification of biological samples. The accurate knowledge on their biological relevance is the critical step that could be translated from some mere technical/industrial advances into a reliable biological disease marker which is helpful in deciphering the oxidative stress puzzle related to neurological disorders. Recent research indicates the value of isoprostanoids in predicting the clinical presentation and evolution of the neurological diseases. This review focuses on the relevance of isoprostanoids as mediators and potential biomarkers in neurological diseases, a heterogeneous family ranging from rare brain diseases to major health conditions that could have worldwide socioeconomic impact in the health sector. The current challenge is to identify the preferential biochemical pathways that actually follow the oxidative reactions in the neurological diseases and the consequence of the specific isoprostanes in the underlying pathogenic mechanisms.http://www.mdpi.com/2076-3921/7/7/88isoprostanesneuroprostanesneurological diseasesbiomarkers |
| spellingShingle | Cinzia Signorini Claudio De Felice Jean-Marie Galano Camille Oger Silvia Leoncini Alessio Cortelazzo Lucia Ciccoli Thierry Durand Joussef Hayek Jetty Chung-Yung Lee Isoprostanoids in Clinical and Experimental Neurological Disease Models Antioxidants isoprostanes neuroprostanes neurological diseases biomarkers |
| title | Isoprostanoids in Clinical and Experimental Neurological Disease Models |
| title_full | Isoprostanoids in Clinical and Experimental Neurological Disease Models |
| title_fullStr | Isoprostanoids in Clinical and Experimental Neurological Disease Models |
| title_full_unstemmed | Isoprostanoids in Clinical and Experimental Neurological Disease Models |
| title_short | Isoprostanoids in Clinical and Experimental Neurological Disease Models |
| title_sort | isoprostanoids in clinical and experimental neurological disease models |
| topic | isoprostanes neuroprostanes neurological diseases biomarkers |
| url | http://www.mdpi.com/2076-3921/7/7/88 |
| work_keys_str_mv | AT cinziasignorini isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT claudiodefelice isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT jeanmariegalano isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT camilleoger isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT silvialeoncini isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT alessiocortelazzo isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT luciaciccoli isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT thierrydurand isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT joussefhayek isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels AT jettychungyunglee isoprostanoidsinclinicalandexperimentalneurologicaldiseasemodels |